Table 2 Predictive effect of pre-chemotherapy sarcopenia on chemotherapy toxicity
From: Correlation between sarcopenia and esophageal cancer: a narrative review
Author, year | Disease, cases | Sarcopenia (proportion) | Chemotherapy regimens | Impact on chemotherapy toxicity or outcomes |
|---|---|---|---|---|
Cédric M. Panje et al. [64] 2019 | EC 61 | 18 (29.5%) | DP (docetaxel + cisplatin) with or without cetuximab | Grade ≥ 3 toxicities↑ |
Ying-Ying Xu et al. [63] 2021 | ESCC 184 | 94 (51.1%) | DP (docetaxel + cisplatin) | Grade 3–4 toxicities (leukopenia, neutropenia, anorexia)↑ OS↓ |
Chunhou Huang et al. [71] 2020 | ESCC 107 | 65 (67%) | Cisplatin + fluorouracil | Grade 3 to 4 mucositis↑ Grade 3 to 4 fever and neutropenia fever↑ OS↓ DFS↓ |
Christine Koch et al. [68] 2019 | GC, GEJC 83 | 30 (36.1%) | FLOT (5-flurouracil, leucovorin, oxaliplatin, and docetaxel) EOX (epirubicin, oxaliplatin, and capecitabine) ECX (epirubicin, cisplatin, capecitabine) | Severe perioperative complications↑ Survival↓ Terminated the chemotherapy significantly earlier |
B.H.L. Tan et al. [66] 2015 | OGC 89 | 44 (49.4%) | ECX (epirubicin, cisplatin, and capecitabine) CF (cisplatin and 5-FU) | DLT↑ |
Yohei Ozawa et al. [40] 2019 | ESCC 82 | 21 (25.6%) | Cisplatin + 5-FU | DFS↓ Postoperative recurrence↑ |
Takayuki Ota et al. [62] 2019 | EC 31 | 16 (51.6%) | FP (cisplatin and 5-fluorouracil (5-FU)) DCF (cisplatin, 5-FU, and docetaxel) | Poor pathological response |
Gilbert Z. Murimwa et al. [65] 2017 | EC 56 | 23 (41%) | Cisplatin + fluorouracil | Acute Grade ≥ 3 toxicity (dysphagia, neutropenia, hospitalization during treatment)↑ |
Poorna Anandavadivelan et al. [67] 2016 | EC 72 | 31 (43%) | Cisplatin/oxaliplatin/carboplatin + 5-fluorouracil | DLT↑ |
Kostan W. Reisinger et al. [75] 2015 | EC 108 | 60 (56%) | CF (cisplatin and 5-FU) PC (paclitaxel/carboplatin) ECC (epirubicin/cisplatin/capecitabine) | Postoperative mortality↑ |
Katsuhiko Nara et al. [76] 2023 | EC 39 | 20 (51.3%) | DCF (docetaxel + cisplatin + 5‑fluorouracil) | FN↑ |
Tsuyoshi Harada et al. [77] 2023 | LAEC 188 | 68 (36.2%) | FP (cisplatin and 5-fluorouracil (5-FU)) DCF (cisplatin, 5-FU, and docetaxel) | RDI↓ |
Nishi S et al. [72] 2023 | EC 36 | 11 (30.6%) | NA | PP↑ |
Dónal Michael McSweeney et al. [70] 2023 | EC 135 | 68 (50.4%) | PC (paclitaxel/carboplatin) Cisplatin + capecitabine or carboplatin + capecitabine | OS↓ Radiation-induced lymphopenia↑ |